Hormone replacement therapy and risk of venous blood clots

By Vania Morelli
Researcher at TREC

Hormone replacement therapy is a treatment used to relieve symptoms related to the menopause. Former studies have shown that hormone replacement therapy is associated with risk of venous blood clots; however, the risk may vary depending on the type of hormone replacement therapy used. A study recently published from the United Kingdom provides a more detailed picture of the blood clot risk for different hormone replacement therapy preparations. According to the authors, the study results can help clinicians and women make treatment choices.

Continue reading

MiRNA signature in extracellular vesicles of ALS patients

By Omri Snir
Researcher at TREC

The potential of microRNAs (miRNAs) and extracellular vesicles (EVs) as biomarkers for venous thromboembolism (VTE) and their possible roles in disease pathogenesis are studied in the field of thrombosis, as well as by researchers in TREC. Saucier et al. studied similar questions in amyotrophic lateral sclerosis (ALS) and reported a series of differentially expressed miRNAs that were detected in circulating plasma EVs in comparison with healthy subjects. The potential target genes of such miRNA and the use as biomarkers for prediction of ALS were examined.

Continue reading

Kan kolesterolsenkende behandling gi mindre blodpropp?

Av Cathrine Ramberg
Stipendiat ved TREC

Ved behandling og forebygging av venøs blodpropp bruker man vanligvis blodfortynnende medisiner. Problemet med denne typen legemiddel er økt risiko for blødning, og derfor behandles de fleste pasientene bare de første 3-12 månedene etter en blodpropp, når risikoen for tilbakefall er størst. I en nyere studie fra Nederland undersøkes det om statinbehandling har en effekt på blodets evne til å levre seg. Forskerne tenker at i så fall vil statiner kunne gis som et supplement til pasienter etter at behandlingen med blodfortynnende medisin er avsluttet.

Continue reading

Curious and nerdy: Meet PhD student Eike Struck (32)

By Dana Meknas
Journalist at TREC

About a year ago, 32 year old Eike Struck started working as a PhD student in TREC. It wasn’t until September this fall, however, that he moved to Tromsø and got installed in the office at University of Tromsø – The Arctic University of Norway. Find out what his projects are about and what it’s like to be a part of TREC in this interview!

Continue reading

Medieoppslag: Den prisvinnende forskeren Sigrid Brækkan (38) er ansatt som professor (Nordlys og Fremover)

Av Dana Meknas
Journalist ved TREC

Både avisa Fremover og avisa Nordlys har skrevet om at Sigrid Brækkan (38) har blitt professor. Det er en svært gledelig nyhet, og du kan lese intervju med Sigrid enten på våre nettsider, eller hos de aktuelle mediene.

Nordlys (pluss): Den prisvinnende forskeren Sigrid Brækkan (38) er ansatt som professor ved UiT: – Det føles veldig bra

Fremover (pluss): Sigrid Brækkan (38) fra Narvik ansatt som professor ved UiT: –⁠ Det føles veldig bra

A new prediction model for development of venous thromboembolism in cancer patients?

Robin Liang
PhD student at TREC

Cancer patients have a high risk of developing venous thromboembolism (VTE), especially in the first 6 months after diagnosis. The risk of VTE can be greatly reduced using anticoagulants to prevent thrombosis, but this treatment brings a high risk of bleeding. This makes it difficult to determine whose risk of thrombosis is greater than the risk of bleeding. Though there are several models that are used in the clinics to predict which cancer patients are likely to benefit from anticoagulation, their accuracy has been disputed. Ingrid Pabinger and colleagues set out to create and validate a clinical prediction model to predict VTE over 6 months in cancer patients.

Continue reading